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Summary
A literature review was conducted to obtain a high-level view of the value of telemedicine in the management of ﬁve
common chronic diseases (asthma, COPD, diabetes, heart failure, hypertension). A total of 141 randomised controlled
trials (RCTs) was identiﬁed, in which 148 telemedicine interventions of various kinds had been tested in a total of 37,695
patients. The value of each intervention was categorised in terms of the outcomes speciﬁed by the investigators in that
trial, i.e. no attempt was made to extract a common outcome from all studies, as would be required for a conventional
meta-analysis. Summarizing the value of these interventions shows, ﬁrst, that most studies have reported positive effects
(n ¼ 108), and almost none have reported negative effects (n ¼ 2). This suggests publication bias. Second, there were no
signiﬁcant differences between the chronic diseases, i.e. telemedicine seems equally effective (or ineffective) in the diseases
studied. Third, most studies have been relatively short-term (median duration 6 months). It seems unlikely that in a chronic
disease, any intervention can have much effect unless applied for a long period. Finally, there have been very few studies
of cost-effectiveness. Thus the evidence base for the value of telemedicine in managing chronic diseases is on the whole
weak and contradictory.
Introduction
Chronic illnesses, such as asthma, COPD, diabetes, heart
failure and hypertension represent a signiﬁcant burden of
disease. Burden of disease is measured in Disability-Adjusted
Life Years (DALYs), which reﬂect years of life lost from
premature death and years of life lived in less than full
health. In high-income countries, asthma, COPD and
diabetes represent 11.1 million DALYs or 7% of the total
DALYs.
1 As well as their signiﬁcance from the perspective of
those affected, chronic diseases also impose huge costs on
the health care systems responsible for managing them. In
the US, the direct health care costs for patients with asthma,
diabetes, heart disease and hypertension were $52.1 billion
in 1996.
2
Does telemedicine have a role in the management of
chronic diseases? Before considering this question, it is
worth thinking about where telemedicine would ﬁt into the
disease management process. Most of us would imagine, a
priori, that closer involvement of health care staff with a
patient who has one or more chronic diseases would reduce
morbidity and perhaps mortality. There is some evidence,
for example, that use of nurse case managers (combined
with a patient education programme) is efﬁcacious.
3 Use of
case managers is one aspect of providing “integrated care”, a
fashionable term with a rather elastic deﬁnition. Integrated
care is commonly thought of as a process that seeks to
achieve seamless and continuous care, tailored to the
individual patient’s needs, and based on a holistic view of
the patient. There are several synonyms, such as disease
management, care management, managed care and
coordinated care. Integrated care programmes seem to have
positive effects on the quality of care, although the widely
varying deﬁnitions and components may lead to
inappropriate conclusions being drawn.
4
How has telemedicine been used to support integrated
care in chronic disease management? Its main roles have
been in providing education (to improve self-management),
in enabling information transfer (e.g. telemonitoring), in
facilitating contact with health professionals (e.g. telephone
support and follow-up) and in improving electronic records.
That is, telemedicine has been used in both the process of
care and the outcome of care.
Note that the term “telemedicine” has a wide deﬁnition –
medicine practised at a distance – and a correspondingly
wide range of telemedicine applications has been trialled in
the management of chronic diseases. The telemedicine
interactions have been of two types, either taking place in
real time (e.g. videoconferencing) or asynchronously (e.g.
store-and-forward transmission of data from a home glucose
meter). Monitoring applications have been entirely
automatic (e.g. passive monitoring of activity using room
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sensors) or have required the patient to do something (e.g.
transmit bodyweight values using the buttons on a
telephone). Educational applications have employed
specially designed home devices, or depended on web
access from PCs or smart phones.
A review conducted in 2003 concluded that telemedicine
looked promising for chronic disease management, but that
good quality studies were scarce and that the
generalizability of most ﬁndings was rather limited.
5 What
has changed in the ensuing nine years? First,
experimentation with telemedicine has continued apace.
There has been a continued increase in the publication of
papers concerning telemedicine and chronic diseases
(Figure 1). The numbers of papers has increased
approximately ﬁve-fold since 2003. Second, there have been
some substantial implementations. For example, the
Veterans Administration in the US has reported some
50,000 patients managed with home telecare.
6 Despite this
enthusiasm, almost nothing is known about the
cost-effectiveness of telemedicine in chronic disease
management.
Cost-effectiveness is a critical matter for the adoption of
any new technique or technology into health care. The
conventional approach to answering questions about
cost-effectiveness is to summarize the results of randomized
controlled trials (RCTs) and produce a pooled estimate of
effect, by conducting a meta-analysis. Generally, the effect
of interest is the Quality-Adjusted Life Year (QALY). If such
an estimate for the cost of a QALY passes an agreed
threshold (e.g. £25-35,000 in the UK NHS), then widespread
implementation of the intervention is likely. Ultimately, if
telemedicine is going to be used on a wide scale in public
healthcare systems, it will need to pass tests such as these.
However, there are signiﬁcant difﬁculties in taking this
approach in the present context. Crucially, there have been
very few studies of cost-effectiveness, so calculating a
pooled estimate is impossible.
Since estimating the cost-effectiveness is unfeasible
because of the lack of data, some lesser assessment of the
value of telemedicine may be the best that can be managed
for the time being. Again, the conventional approach is a
meta-analysis, examining a quantitative outcome such as
mortality, emergency department visits or length of stay in
hospital. Such analyses have indeed been conducted for
speciﬁc outcomes in certain chronic diseases. Here the
problem is that the published trials have employed a wide
range of outcome measures, so that a pooled estimate of any
one outcome reduces the size of the dataset very
considerably. For example, there are at least 11 RCTs of
telemedicine in COPD, but the published estimate of the
risk ratio for mortality was based on only three studies.
7
Since conventional meta-analysis cannot yet provide a
robust summary of this very heterogeneous ﬁeld, a different
procedure must be used if the value of telemedicine in
chronic disease management is to be estimated. The present
study therefore takes a new approach, in order to obtain a
high-level view of the value of telemedicine in chronic
disease management.
Methods
The analysis was conﬁned to RCTs in which one or more
telemedicine interventions had been compared with a
control group. It was restricted to patients with one of the
following common chronic diseases: asthma, COPD,
diabetes, heart failure, hypertension. The telemedicine
intervention could include telephone support,
telemonitoring, videoconferencing, etc. The “value” of the
trial result was deﬁned in terms of the outcomes speciﬁed by
the investigators in each study individually. A synthesis was
carried out by meta-regression.
Identiﬁcation of studies
The studies of interest were RCTs concerning the use of
telemedicine in chronic disease. Candidate studies were
identiﬁed in a three stage process. First, systematic reviews of
the use of telemedicine in the chronic diseases of interest
were identiﬁed, and the reference lists of these reviews were
searched by hand. Second, a computerised literature search
was conducted to identify individual RCTs directly. Finally,
the reference lists of included studies were searched by hand.
Computerized searching
Computerized searches of the Medline database were
conducted in July/August 2011 to identify systematic
reviews, and to identify RCTs. The search terms were:
(1) Telemedicine AND;
(2) Randomized controlled trial/systematic review AND;
(3) Asthma OR COPD OR diabetes OR heart failure OR
hypertension.
Non-English language papers were included.
Figure 1 Medline publications on telemedicine and ﬁve chronic
diseases. There were 1324 publications between 1990 and 2011.
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Selection of studies
Candidate studies were selected for further examination
based on the abstract; full copies of the articles were
then examined to conﬁrm that they met the following
inclusion criteria. Studies were included if they reported:
(1) An RCT;
(2) A telemedicine intervention, such as telemonitoring or
telephone support;
(3) Patients with a single chronic disease, or if multiple
disease groups had been studied, then the results had
to be separately reported for each disease group of
interest.
Data extraction
The following information was extracted from each of the
studies:
No of subjects
Type of patient, e.g. disease and severity
Nature of the intervention. In addition, details were recorded
about whether there was-
Routine voice contact with a person such as a case manager,
nurse specialist or pharmacist
Voice contact with an interactive voice response (IVR) system
Video contact with a health professional, e.g. videoconferencing
Messaging with a health professional, e.g. using email, web
messaging or online chat
Telemonitoring, e.g. automatic transmission of data such as
symptoms or vital signs
Duration (months)
Primary and other outcomes
Result
Overall value of intervention.
The overall value of the intervention was rated in terms of
the outcomes speciﬁed for the study in question, with the
effect categorised on a 5-point scale, see Table 1.
Synthesis
The relation between the value of the interventions trialled
(i.e. the estimates of effect) and various potential
explanatory variables was ﬁrst examined graphically.
Possible predictors were then examined collectively using
regression modelling. Since the dependent variable was
categorical, an ordered logit regression was employed, using
a standard package (Gretl. See http://gretl.sourceforge.net/).
Results
Identiﬁcation and selection of studies
In the ﬁrst stage of the identiﬁcation process, a total of 22
systematic reviews was identiﬁed relating to the use of
telemedicine in the chronic diseases of interest.
7–28 In the
second stage, a total of 264 reports of RCTs was identiﬁed.
After screening these papers and examining the reference
lists of those included, there was a ﬁnal total of 141 RCTs
which met the inclusion criteria, see Table 2. These papers
reported trials of 148 interventions, i.e. some trials had
multiple experimental arms.
RCTs and interventions trialled
In asthma, trials of 20 interventions were identiﬁed, see
Table 3 (see online only supplementary data: http://
jtt.rsmjournals.com/lookup/suppl/doi:10.1258/
jtt.2012.120219/-/DC1). These trials involved a total of
10,406 patients. Outcome measures commonly employed
were healthcare utilization, symptoms and quality of life.
In COPD, trials of 11 interventions were identiﬁed; two
articles contained the details about one trial, see Table 4 (see
online only supplementary data: http://
jtt.rsmjournals.com/lookup/suppl/doi:10.1258/
jtt.2012.120219/-/DC1). The trials involved a total of 1104
patients. Outcome measures commonly employed were
hospital admissions and quality of life.
In diabetes, trials of 39 interventions were identiﬁed;
there were three trials in which the details were contained
in two reports each, see Table 5 (see online only
supplementary data: http://jtt.rsmjournals.com/lookup/
suppl/doi:10.1258/jtt.2012.120219/-/DC1). The trials
involved a total of 4970 patients. Outcome measures
commonly employed were HbA1c, quality of life and
self-efﬁcacy.
In heart failure, trials of 61 interventions were identiﬁed;
there were six trials in which the details were contained in
two reports each, see Table 6 (see online only
supplementary data: http://jtt.rsmjournals.com/lookup/
suppl/doi:10.1258/jtt.2012.120219/-/DC1). The trials
involved a total of 16,388 patients. Outcome measures
commonly employed were mortality, hospital admissions,
quality of life and healthcare costs.
In hypertension, trials of 17 interventions were
identiﬁed – there were 14 RCTs, see Table 7 (see online only
supplementary data: http://jtt.rsmjournals.com/lookup/
suppl/doi:10.1258/jtt.2012.120219/-/DC1). These trials
involved a total of 4827 patients. Outcome measures
commonly employed were blood pressure and healthcare
costs.
Table 1 Categorisation of the value of the intervention
Value Criterion Score
Positive Primary outcome signiﬁcantly better (P , 0.05) in the
intervention group compared to control
5
Weakly
positive
One or more secondary outcomes signiﬁcantly better, if
the primary outcome was not signiﬁcantly better
4
No effect No signiﬁcant difference between intervention and
control groups
3
Weakly
negative
One or more secondary outcomes signiﬁcantly worse, if
the primary outcome was not signiﬁcantly worse
2
Negative Primary outcome signiﬁcantly worse in the intervention
group compared to control
1
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The 141 RCTs involved a total of 37,695 patients, i.e. an
average trial size of about 270 patients. There was a
tendency for the trials of patients with diabetes to be
slightly smaller than the norm, and for the trials of patients
with asthma to be slightly larger than the norm, see
Figure 2. There was a linear relationship, though not
signiﬁcant, between the numbers of interventions trialled
and the total number of patients in those trials.
Effect estimates
Most studies reported favourable effects: either positive
(n ¼ 65) or weakly positive (n ¼ 43) in terms of the
outcomes speciﬁed by the investigators in their trials.
There were 38 studies in which the intervention was not
signiﬁcantly different from the control, and only two (one
weakly negative and one negative) in which the
intervention was worse than the control. That is, 73% of
studies were favourable to the intervention, 26% were
neutral, and 1% were unfavourable.
Heterogeneity
In the absence of bias and between-study heterogeneity, the
scatter in the effect estimates will be due to sampling
variation alone. A plot of the effect estimates from
individual studies against some measure of the precision of
each study will resemble a symmetrical inverted funnel.
Using the square root of the sample size as an estimate of
precision showed that there was considerable heterogeneity
in the dataset, see Figure 3.
Potential explanatory variables
The relation between the duration of the intervention and
the effect is shown in Figure 4. There was no obvious
tendency for interventions applied for longer periods to
produce more positive results. An ordered logit regression
was not signiﬁcant.
Figure 3 Funnel plot
Figure 2 Size of the trials. The solid line shows the linear regression
Table 2 Identiﬁcation and selection of studies
Asthma COPD Diabetes Heart failure Hypertension Total
Systematic reviews 1 5  69 1 2 2
No of papers retrieved in initial search 21 20 106 75 42 264
No of papers included in the present study 20 11 39 57 14 141
No of interventions   20 11 39 61 17 148
 one review concentrated on the organizational process, rather than health care outcomes
9
  some trials had multiple experimental arms
Figure 4 Duration of interventions
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positive. In the individual diseases, the median effect was
weakly positive for asthma, diabetes, heart failure and
hypertension, and positive for COPD. The effect in different
disease types is summarised in Figure 5. There were no
signiﬁcant differences between the different disease types
(Kruskal Wallis P ¼ 0.96).
The effect in trials using telemonitoring is shown in
Figure 6; there was no signiﬁcant difference in effect
between interventions which employed telemonitoring and
those which did not. The effect in trials using routine voice
contact is shown in Figure 7; there was no signiﬁcant
difference in effect between interventions which employed
routine voice contact and those which did not. The effect in
trials using videoconferencing is shown in Figure 8; there
was no signiﬁcant difference in effect between
interventions which employed videoconferencing and
those which did not.
Figure 6 Telemonitoring. Box plot attributes as for Figure 5
Figure 5 Disease type. The boundaries of the boxes indicate the 25th
and 75th percentiles, and a line within the box marks the median. The
whiskers (error bars) above and below the boxes indicate the 90th and
10th percentiles. Potential outliers are shown individually
Figure 7 Routine voice contact. Box plot attributes as for Figure 5
Figure 8 Videoconferencing. Box plot attributes as for Figure 5
Figure 9 Number of subjects
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The relation between the number of subjects and the
effect is shown in Figure 9. There was no obvious tendency
for trials in which large numbers of subjects had been
employed to produce more positive results. An ordered logit
regression was not signiﬁcant.
The relation between the year of publication and the
effect is shown in Figure 10. There was a tendency for
studies which had been published earlier to report more
positive ﬁndings. An ordered logit regression was signiﬁcant
at P, 0.05.
Synthesis
In an ordered logit regression with all possible predictors,
none was signiﬁcant except year of publication (P ¼ 0.02).
Discussion
During the last 20 years, more than 1300 Medline papers
have been published concerning the use of telemedicine in
the ﬁve chronic diseases considered here. Approximately
one in ten of these studies have been formal randomised
trials. A wide range of outcomes has been reported in these
experiments, which makes a conventional meta-analysis of
the entire dataset unfeasible. The present work was
undertaken in order to obtain a high-level overview of the
value of telemedicine in chronic disease management in a
general sense. In doing so, data were considered from RCTs
in which more than one intervention had been trialled.
Multiplicity adjustment
In a trial with multiple experimental arms, the question
arises whether a multiplicity adjustment is required to reduce
the probability of a false-positive result, i.e. with two
treatment arms, each intervention group will be compared
separately with the same control group. One possibility, for
example, would be to use a Bonferroni adjustment. However,
the consensus of opinion is that a multiplicity adjustment
would not be necessary if the aim of the trial was to answer
questions about the efﬁcacy of each intervention separately,
i.e. the interpretation of the results of one comparison had
no direct bearing on the interpretation of the results of the
others.
29 In the present context, the multi-arm studies found
in the review investigated interventions such as telephone
support and telemonitoring, which can be considered
independent. Thus a multiplicity adjustment was not
required for the present analysis.
Systematic reviews
During the identiﬁcation of RCTs for the present study, a
total of 22 systematic reviews was identiﬁed concerning the
use of telemedicine in the ﬁve chronic diseases of interest.
In approximately half of these reviews, the authors provided
a qualitative summary of the value of telemedicine, usually
in the form of a narrative review; none of these concluded
negatively, i.e. that telemedicine was unhelpful in chronic
disease management, see Table 8.
The other half of the reviews provided pooled estimates of
various quantitative outcomes. There were four quantitative
outcomes which were potentially applicable in all ﬁve
diseases:
(1) Quality of life;
(2) Emergency department visits;
(3) Hospitalization;
(4) Mortality.
In addition, there were three quantitative outcomes which
were speciﬁc to diabetes:
(1) HbA1c;
(2) Severe hypoglycaemia;
(3) Diabetic ketoacidosis.
Between them, the 12 systematic reviews provided 23
pooled estimates of effect, of which approximately half
showed telemedicine to provide signiﬁcantly better
outcomes than the control condition. Conversely, the other
half of the pooled estimates showed telemedicine to be no
better than the control condition. This emphasises the
rather weak and unsatisfactory conclusions which can be
drawn from the systematic reviews presently available.
Heart failure
Of the 22 systematic reviews identiﬁed, the largest
number (9) concerned the use of telemedicine in heart
failure. These reviews, which were published over a
nine-year period, provide eight pooled estimates of effect,
all except one being signiﬁcantly positive in favour of
telemedicine. Of all the chronic diseases considered in the
present study, therefore, the evidence would appear most
favourable for heart failure. Indeed, the appearance of an
authoritative Cochrane review that favoured the use of
telemedicine (telephone support or telemonitoring) in
Figure 10 Year of publication
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17 would normally signal acceptance of efﬁcacy
by the scientiﬁc community and potentially pave the way
for widespread trials of effectiveness. Unfortunately, there
have been two subsequent reports
30,31 from large,
well-powered RCTs which are contradictory, and at the time
of writing, we expect the Cochrane review to be revised and
re-issued to reﬂect this.
Overview
To avoid the problem of requiring a common outcome from
all trials, as would be needed for a conventional meta-
analysis, the present study adopted a different approach in
whichthevalueofeachinterventionwascategorisedinterms
of the outcomes speciﬁed by the investigators in that trial.
From this, it can be seen that the majority of trials report
positive effects, i.e. there is a strong suspicion of publication
bias. This is supported by the observation that more recent
publications tend to report weaker effects. Publication bias
was also suggested by the asymmetric funnel plot for the
dataset. While this is certainly a plausible explanation of the
overwhelmingly positive ﬁndings reported, it is not the only
one.
32 There is likely to be true heterogeneity because of
differences between the interventions and differences
between the diseases.
The present review suggests that there are no major
differences in the value of the telemedicine intervention
between the disease types. Furthermore, neither
telemonitoring nor videoconferencing appear to be
superior to telephone support. Most studies have been
relatively short-term which, in the case of chronic diseases,
may weaken their power to demonstrate an effect. The work
of Shea et al.,
33 who reported 5-year follow-up in patients
with diabetes, demonstrates that long-term telemedicine
interventions are possible.
Awide range of outcomes has been employed in the trials
reviewed. However, there have been few studies in which
cost-effectiveness has been measured. The work by Hebert
et al.
34 reporting QALY data for telemedicine in heart
failure, therefore represents an exemplar.
On the basis of the work reviewed, it is not possible to
state that telemedicine of a particular type will be
cost-effective in the management of one or more chronic
diseases. After nearly 20 years of randomised trials work,
this seems both surprising and disappointing. Nonetheless,
the majority of the studies conducted have reported positive
effects in terms of the outcomes speciﬁed in those trials.
This raises the possibility that the beneﬁcial effect reported
is not due to telemedicine itself, so much as to the increased
attention due to the experimental intervention, i.e. that a
Hawthorne effect is at least partly responsible. Future work
should be designed to separate the true effects of
telemedicine from putative placebo effects.
Limitations
The present study had certain limitations. First, although the
search for studies was conducted largely in accordance with
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218 Journal of Telemedicine and Telecare Volume 18 Number 4 2012the procedure for a systematic review, there may be other
RCTs that could have been found. Second, the value of each
study was assumed to be the same in the meta-regression, i.e.
no attempt was made to weight the studies. Third, other
chronic diseases may be of interest in addition to the ﬁve
common chronic diseases which were studied. Finally,
synthesizingdisparateoutcomesdataindifferentdiseaseshas
not been attempted before in telemedicine work, so far as I
am aware. It is an acknowledged limitation of this new
approach that the theoretical foundation remains to be
developed. In the meantime, it can at least be regarded as a
qualitative technique.
Future work
The present study raises a number of questions about the
intrinsic value of telemedicine in the management of
chronic disease. It would therefore be useful if future studies
were designed very carefully, in order to identify the true
value of distance support. It would also be valuable to future
reviewers if a minimum dataset could be agreed for the
outcome measures. Quantitative indices, from which
pooled estimates of effect can be calculated, and which are
applicable across all disease groups include:
(1) Quality of life (as measured on the scale appropriate to
the disease in question);
(2) Cost to society;
(3) Emergency department visits;
(4) Days in hospital;
(5) Mortality.
The last three may be further categorised as “all-cause” or
disease-speciﬁc.
Finally, it seems unlikely that in a chronic disease, any
intervention can have much effect unless applied for a long
period. Future studies might consider interventions lasting
years rather than months.
Conclusion
The evidence base for the value of telemedicine in managing
chronic diseases is on the whole weak and contradictory.
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